| Year |
Citation |
Score |
| 2020 |
Holder SL, Warrick J, Zhu J, Drabick JJ, Joshi M. A phase Ib study targeting PIM1 and CDK4/6 kinases in metastatic renal cell carcinoma (PICKRCC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps771 |
0.364 |
|
| 2019 |
Joshi M, Warrick JI, Yin M, Holder SL, Drabick JJ. Need for a personalized approach for muscle invasive bladder cancer: role of tumor biology in response to neoadjuvant chemotherapy. Translational Andrology and Urology. 8: S99-S103. PMID 31143680 DOI: 10.21037/Tau.2018.12.04 |
0.339 |
|
| 2019 |
Wheelden M, Kaag M, Zhu J, Holder SL, Drabick JJ, Raman JD, Tuanquin L, Merrill S, Warrick J, Joshi M. Small cell bladder carcinoma: Single institution experience. Journal of Clinical Oncology. 37: 468-468. DOI: 10.1200/Jco.2019.37.7_Suppl.468 |
0.308 |
|
| 2018 |
Joshi M, Tuanquin L, Kaag M, Zakharia Y, Liao J, Merrill S, Musapatika D, DeGraff D, Zheng H, Warrick J, Holder SL, Stein M, Drabick JJ. Phase Ib study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial cancer of the bladder: BTCRC-GU15-023 study. Journal of Clinical Oncology. 36: 455-455. DOI: 10.1200/Jco.2018.36.6_Suppl.455 |
0.307 |
|
| 2017 |
Small J, Washburn E, Millington K, Zhu J, Holder SL. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget. 8: 95116-95134. PMID 29221116 DOI: 10.18632/Oncotarget.19618 |
0.386 |
|
| 2017 |
Holder SL, Small J. An evaluation of abemaciclib activity in combination with sunitinib in renal cell carcinoma. Journal of Clinical Oncology. 35: 452-452. DOI: 10.1200/Jco.2017.35.6_Suppl.452 |
0.39 |
|
| 2016 |
Joshi M, Millis SZ, Arguello D, Holder SL, Lamm D, Reddy S, Belani C, Drabick JJ, Vogelzang NJ. Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. European Urology Focus. PMID 28753770 DOI: 10.1200/Jco.2015.33.15_Suppl.4528 |
0.303 |
|
| 2016 |
Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systemic Review and Two-Step Meta-Analysis. The Oncologist. PMID 27053504 DOI: 10.1634/Theoncologist.2015-0440 |
0.318 |
|
| 2015 |
Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. PMID 26695546 DOI: 10.18632/Oncotarget.6657 |
0.339 |
|
| 2015 |
Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clinical Genitourinary Cancer. PMID 26303589 DOI: 10.1016/J.Clgc.2015.07.003 |
0.304 |
|
| 2015 |
Al-Marrawi MY, Holder SL. Current Immunotherapies for Renal Cell Carcinoma. Current Molecular Pharmacology. PMID 26177641 DOI: 10.2174/1874467208666150716121116 |
0.337 |
|
| 2015 |
Holder SL, Drabick J, Zhu J, Joshi M. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer. Cancer Biology & Therapy. 16: 207-9. PMID 25756508 DOI: 10.1080/15384047.2014.1002687 |
0.329 |
|
| 2015 |
Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, Drabick JJ, Joshi M. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biology & Therapy. 16: 28-33. PMID 25692619 DOI: 10.4161/15384047.2014.972843 |
0.389 |
|
| 2015 |
Small JS, Holder SL. Abstract 5323: Targeting PIM1 and CDK4/6 kinases in renal cell carcinoma Cancer Research. 75: 5323-5323. DOI: 10.1158/1538-7445.Am2015-5323 |
0.465 |
|
| 2014 |
Holder SL, Abdulkadir SA. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Current Cancer Drug Targets. 14: 105-14. PMID 24274399 DOI: 10.2174/1568009613666131126113854 |
0.404 |
|
| 2014 |
Matthew EM, Zhou L, Lim B, Lamparella NE, Dicker DT, Gallant J, Joshi M, Holder SL, Harouaka R, Zheng S, Drabick JJ, Truica CI, Yang Z, El-Deiry WS. Abstract 4822: Immunophenotyping circulating tumor cells in patients with unknown primary Cancer Research. 74: 4822-4822. DOI: 10.1158/1538-7445.Am2014-4822 |
0.366 |
|
| 2007 |
Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorganic & Medicinal Chemistry. 15: 6463-73. PMID 17637507 DOI: 10.1016/J.Bmc.2007.06.025 |
0.569 |
|
| 2007 |
Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Molecular Cancer Therapeutics. 6: 163-72. PMID 17218638 DOI: 10.1158/1535-7163.Mct-06-0397 |
0.603 |
|
| 2004 |
Lilly MB, Holder S, Zemskova M, Neidigh J. Use of a Homology Model of the PIM-1 Kinase To Identify Variant Flavonoids Having Selective Inhibitory Activity Against PIM-1. Blood. 104: 2566-2566. DOI: 10.1182/Blood.V104.11.2566.2566 |
0.595 |
|
| 2003 |
Yan B, Zemskova M, Holder S, Chin V, Kraft AS, Koskinen PJ, Lilly MB. The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death Journal of Biological Chemistry. 278: 45358-45367. PMID 12954615 DOI: 10.1074/Jbc.M307933200 |
0.576 |
|
| Show low-probability matches. |